Skip to main content

Patisiran Can Preserve Functional Capacity in ATTR Amyloidosis

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Oct. 26, 2023 -- For patients with transthyretin amyloidosis (ATTR amyloidosis), administration of an RNA interference therapeutic agent, patisiran, over 12 months results in preserved functional capacity, according to a study published in the Oct. 26 issue of the New England Journal of Medicine.

Mathew S. Maurer, M.D., from the Columbia University Irving Medical Center in New York City, and colleagues conducted a phase 3 randomized trial involving patients with hereditary ATTR cardiac amyloidosis who were assigned to receive patisiran or placebo once every three weeks for 12 months (181 and 179 patients, respectively).

The researchers found that the decline in the six-minute walk distance was lower in the patisiran group than the placebo group at month 12 (Hodges-Lehmann estimate of median difference, 14.69 m); the Kansas City Cardiomyopathy Questionnaire-Overall Summary score increased and decreased in the patisiran and placebo groups, respectively (least-squares mean difference, 3.7 points). For the second secondary end point (composite of death from any cause, cardiovascular events, and change from baseline in the six-minute walk distance over 12 months), no significant benefits were observed. Compared with those receiving placebo, patients in the patisiran group more often had infusion-related reactions, arthralgia, and muscle spasms.

"Studies of longer duration are needed to determine whether the benefits observed with the reduction of transthyretin mediated by RNA interference are associated with a reduction in mortality and improved hospitalization outcomes in patients with ATTR cardiac amyloidosis," the authors write.

The study was funded by Alnylam Pharmaceuticals, the manufacturer of patisiran.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted October 2023

Read this next

Acoramidis Beneficial in Transthyretin Amyloid Cardiomyopathy

THURSDAY, Jan. 11, 2024 -- Acoramidis yields a significantly better four-step primary hierarchical outcome, including aspects of mortality and morbidity, than placebo for patients...

Prognostic Factors ID'd for Stage IIIb AL Amyloidosis

THURSDAY, Aug. 24, 2023 -- For patients with stage IIIb amyloid light chain (AL) amyloidosis, baseline factors predictive of treatment outcomes and survival have been identified...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.